AIM: To evaluate the potential of thioredoxin (TXN) and thioredoxin-interacting protein (TXNIP) expression as biomarkers for predicting gastric cancer recurrence. METHODS: TXN and TXNIP expression levels were acquired from gene expression microarray data for 65 human gastric cancer tissues. We determined whether each gene expression level was associated with cancer recurrence and investigated the relationship between the two genes. For validation, the expression levels of TXN and TXNIP were measured by quantitative real-time reverse transcription polymerase chain reaction in 68 independent stage III gastric cancer patients. The correlation between gene expression and cancer prognosis was evaluated. Immunohistochemical staining was performed to investigate the protein expression levels of TXN and TXNIP and to characterize the expression patterns of each protein. RESULTS: TXN was a prognosis-related gene (P = 0.009), whereas TXNIP, a TXN inhibitor, demonstrated a negative correlation with TXN in the gene expression microarray data. In the 68 stage III patients, the expression levels of both TXN and TXNIP had a statistically significant effect on recurrence-free survival (RFS, P = 0.008 and P = 0.036, respectively). The low TXN and high TXNIP expression group exhibited a better prognosis than the other groups, and the high TXN and low TXNIP expression group exhibited a poorer prognosis (P < 0.001 for RFS and P = 0.001 for overall survival). More than half of the patients in the simultaneously high TXN and low TXNIP expression group experienced a recurrence within 1 year after curative surgery, and the 5-year survival rate of the patients in this group was 29%, compared with 89% in the low TXN and high TXNIP expression group. The TXN protein was overexpressed in 65% of the gastric cancer tissues, whereas the TXNIP protein was underexpressed in 85% of the cancer cells. In a correlation analysis, TXN and TXNIP were highly correlated with many oncogenes and tumor suppressors as well as with genes related to energy, protein synthesis and autophagy. CONCLUSION: TXN and TXNIP are promising prognostic markers for gastric cancer, and performing personalized adjuvant treatment based on TXN and TXNIP expression levels would be an effective practice in the treatment of gastric cancer.
AIM: To evaluate the potential of thioredoxin (TXN) and thioredoxin-interacting protein (TXNIP) expression as biomarkers for predicting gastric cancer recurrence. METHODS:TXN and TXNIP expression levels were acquired from gene expression microarray data for 65 humangastric cancer tissues. We determined whether each gene expression level was associated with cancer recurrence and investigated the relationship between the two genes. For validation, the expression levels of TXN and TXNIP were measured by quantitative real-time reverse transcription polymerase chain reaction in 68 independent stage III gastric cancerpatients. The correlation between gene expression and cancer prognosis was evaluated. Immunohistochemical staining was performed to investigate the protein expression levels of TXN and TXNIP and to characterize the expression patterns of each protein. RESULTS:TXN was a prognosis-related gene (P = 0.009), whereas TXNIP, a TXN inhibitor, demonstrated a negative correlation with TXN in the gene expression microarray data. In the 68 stage III patients, the expression levels of both TXN and TXNIP had a statistically significant effect on recurrence-free survival (RFS, P = 0.008 and P = 0.036, respectively). The low TXN and high TXNIP expression group exhibited a better prognosis than the other groups, and the high TXN and low TXNIP expression group exhibited a poorer prognosis (P < 0.001 for RFS and P = 0.001 for overall survival). More than half of the patients in the simultaneously high TXN and low TXNIP expression group experienced a recurrence within 1 year after curative surgery, and the 5-year survival rate of the patients in this group was 29%, compared with 89% in the low TXN and high TXNIP expression group. The TXN protein was overexpressed in 65% of the gastric cancer tissues, whereas the TXNIP protein was underexpressed in 85% of the cancer cells. In a correlation analysis, TXN and TXNIP were highly correlated with many oncogenes and tumor suppressors as well as with genes related to energy, protein synthesis and autophagy. CONCLUSION:TXN and TXNIP are promising prognostic markers for gastric cancer, and performing personalized adjuvant treatment based on TXN and TXNIP expression levels would be an effective practice in the treatment of gastric cancer.
Entities:
Keywords:
Biomarker; Gastric cancer; Prognosis; Thioredoxin; Thioredoxin-interacting protein
Authors: Daniele Santini; Bruno Vincenzi; Maria Elisabetta Fratto; Giuseppe Perrone; Raymond Lai; Vincenzo Catalano; Carol Cass; Pier Adelchi Ruffini; Chiara Spoto; Pietro Muretto; Sergio Rizzo; Andrea Onetti Muda; John R Mackey; Antonio Russo; Giuseppe Tonini; Francesco Graziano Journal: J Cell Physiol Date: 2010-05 Impact factor: 6.384
Authors: Amanda F Baker; Mei Y Koh; Ryan R Williams; Brian James; Huamin Wang; Wendy R Tate; Alfred Gallegos; Daniel D Von Hoff; Haiyong Han; Garth Powis Journal: Pancreas Date: 2008-03 Impact factor: 3.327
Authors: Altaf A Dar; Alexander Zaika; Maria B Piazuelo; Pelayo Correa; Tatsuki Koyama; Abbes Belkhiri; Kay Washington; Antoni Castells; Manuel Pera; Wael El-Rifai Journal: Cancer Date: 2008-04-15 Impact factor: 6.860
Authors: J-S Kim; M-A Kim; T M Kim; S-H Lee; D-W Kim; S-A Im; T-Y Kim; W H Kim; H-K Yang; D S Heo; Y-J Bang; K-U Lee; K-J Choe; N K Kim Journal: Br J Cancer Date: 2009-03-10 Impact factor: 7.640
Authors: Erika Seki Kioshima; Patrícia de Souza Bonfim de Mendonça; Marcus de Melo Teixeira; Isis Regina Grenier Capoci; André Amaral; Franciele Abigail Vilugron Rodrigues-Vendramini; Bruna Lauton Simões; Ana Karina Rodrigues Abadio; Larissa Fernandes Matos; Maria Sueli Soares Felipe Journal: J Fungi (Basel) Date: 2021-02-02
Authors: Caroline M Woolston; Srinivasan Madhusudan; Irshad N Soomro; Dileep N Lobo; Alexander M Reece-Smith; Simon L Parsons; Stewart G Martin Journal: Redox Biol Date: 2013-05-23 Impact factor: 11.799